Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.34 |
| ▸ | G6PD | P11413 | 1/20 | 0.33 |
| ▸ | IDE | P14735 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15553924 | 0.84 | PTGS2 (0.35) | ENPP2PTGS2LMNA | |
| SCHEMBL4199969 | 0.81 | PTGS2 (0.30) | PTGS2 | |
| SCHEMBL4190368 | 0.77 | CA2 (0.46) | LMNAL3MBTL1 | |
| SCHEMBL4337198 | 0.77 | LCK (0.43) | SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL1334156 | 0.76 | ENPP2 (0.48) | ENPP2PTGS2G6PDIDESMN1; SMN2 | |
| SCHEMBL4190092 | 0.73 | ALDH1A1 (0.42) | SMN1; SMN2LMNA | |
| SCHEMBL4201595 | 0.73 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL3507953 | 0.72 | PTGS2 (0.41) | ENPP2PTGS2L3MBTL1 | |
| SCHEMBL1965864 | 0.72 | LMNA (0.38) | ENPP2PTGS2LMNA | |
| SCHEMBL5042103 | 0.72 | PTGS2 (0.38) | ENPP2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309735-B2 | Heterocyclic compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2012-11-13 | — | — | US | claimed |
| US-20090203745-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-08-13 | — | — | US | claimed |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2009-04-23 | — | — | US | claimed |
| EP-2024357-A2 | NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jereni AG (DE) | 2009-02-18 | — | — | EP | claimed |
| EP-1979342-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | Jerini AG (DE) | 2008-10-15 | — | — | EP | claimed |
| WO-2007131764-A2 | NEW HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-11-22 | — | — | WO | claimed |
| WO-2007088041-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | JERINI AG (DE) | 2007-08-09 | — | — | WO | claimed |
| US-8927534-B2 | Compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8455511-B2 | Pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8309735-B2 | Heterocyclic compounds for the inhibition of integrins and use thereof | SHIRE ORPHAN THERAPIES GMBH (DE) | 2012-11-13 | — | — | US | disclosed |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-06-02 | — | — | US | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-1781652-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH TETRAHYDROPYRIDINE AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1758903-A1 | PYRROLOPYRAMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006001501-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH TETRAHYDROPYRIDINE AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | WO | disclosed |
| WO-2006001511-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | WO | disclosed |
| US-20050209253-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| EP-1467997-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | Taisho Pharmaceutical Co. Ltd. (JP) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004058767-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203745-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | ITGB1, ITGA2, ITGB2 | ENPP2 201/4885PTGS2 1760/4885G6PD 1505/4885 |
| US-20110130364-A1 | PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP | HRH2, HRH4, CRHR1 | ENPP2 425/4885PTGS2 252/4885G6PD 2600/4885 |
| US-20090104116-A1 | COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE THEREOF | ITGA1, ITGB1, ITGA5 | ENPP2 976/4885PTGS2 1276/4885G6PD 1120/4885 |
| US-20050209253-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | HRH2, HRH4, HRH1 | ENPP2 575/4885PTGS2 256/4885G6PD 2879/4885 |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | CRHR1, HRH2, CRHR2 | ENPP2 654/4885PTGS2 305/4885G6PD 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.